Oyster Point Pharma (NASDAQ:OYST) Director Vida Ventures, Llc purchased 10,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $4.51 per share, with a total value of $45,100.00.

NASDAQ OYST traded down $0.51 during trading on Tuesday, hitting $14.65. 49,100 shares of the stock traded hands, compared to its average volume of 61,864. Oyster Point Pharma has a 12-month low of $14.14 and a 12-month high of $19.01.

About Oyster Point Pharma

Oyster Point Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis.

Recommended Story: Key terms to understand channel trading

Receive News & Ratings for Oyster Point Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oyster Point Pharma and related companies with MarketBeat.com's FREE daily email newsletter.